Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;7(1):90-7.
doi: 10.1097/JTO.0b013e31823c5c32.

Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma

Ping Yang  1 , Kimary Kulig, Jennifer M Boland, Michele R Erickson-Johnson, Andre M Oliveira, Jason Wampfler, Aminah Jatoi, Claude Deschamps, Randolph Marks, Connie Fortner, Shawn Stoddard, Francis Nichols, Julian Molina, Marie-Christine Aubry, Hui Tang, Eunhee S Yi
Affiliations

Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma

Ping Yang et al. J Thorac Oncol. 2012 Jan.

Abstract

Introduction: The EML4-anaplastic lymphoma kinase (ALK) translocation is a recognized oncogenic driver in non-small cell lung cancer. We investigated immunohistochemistry (IHC) screening with fluorescence in situ hybridization (FISH) confirmation for ALK detection and estimated the prevalence of ALK positivity in our patient cohort of never-smokers, together with differences in clinical outcomes and prognostic factors for patients with ALK-positive and ALK-negative tumors.

Methods: We designed a three-phase study (training, validation, and testing) in 300 never-smokers with lung adenocarcinoma from the observational Mayo Clinic Lung Cancer Cohort. Tumor samples were tested using IHC and FISH, and concordance between the methods was assessed. Clinical outcomes were assessed via 5-year progression- or recurrence-free survival from diagnosis. Prognostic factors for ALK-positive tumors and metastases were also investigated.

Results: ALK-positive patients were significantly (p < 0.05) younger and had higher grade tumors than ALK-negative patients. ALK positivity was 12.2% by IHC and confirmed at 8.2% of tumors by FISH, with complete concordance between IHC 3+/0 and FISH+/- assessments, respectively. Five-year risk of progression or recurrence was doubled for patients with ALK-positive compared with ALK-negative tumors; ALK-positive tumors also appeared to be associated with a higher risk of brain and liver metastases.

Conclusions: Our findings suggest that ALK positivity is associated with a significantly poor outcome in nonsmoking-related adenocarcinoma and that ALK-positive tumors may be associated with an increased risk of brain and liver metastases compared with ALK-negative disease. Consequently, an unmet medical need exists in ALK-positive lung cancer patients, and effective ALK-specific therapies are needed.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: KK is an employee of Pfizer, Inc.

Figures

Figure 1
Figure 1
(A) Stage-adjusted progression- or recurrence-free survival (PFS/RFS) survival curves for immunohistochemistry (IHC)3+ (positive) versus IHC0/1+ (negative) cases.a (B) Stage-adjusted PFS/RFS survival curves for fluorescence in-situ hybridization (FISH)-positive and FISH-negative cases.a (C) Stage-adjusted PFS/RFS survival curves for FISH+/IHC3+ (positive) and FISH-negative/IHC0/1+ (negative) casesa aTable 2 Select model data
Figure 1
Figure 1
(A) Stage-adjusted progression- or recurrence-free survival (PFS/RFS) survival curves for immunohistochemistry (IHC)3+ (positive) versus IHC0/1+ (negative) cases.a (B) Stage-adjusted PFS/RFS survival curves for fluorescence in-situ hybridization (FISH)-positive and FISH-negative cases.a (C) Stage-adjusted PFS/RFS survival curves for FISH+/IHC3+ (positive) and FISH-negative/IHC0/1+ (negative) casesa aTable 2 Select model data
Figure 1
Figure 1
(A) Stage-adjusted progression- or recurrence-free survival (PFS/RFS) survival curves for immunohistochemistry (IHC)3+ (positive) versus IHC0/1+ (negative) cases.a (B) Stage-adjusted PFS/RFS survival curves for fluorescence in-situ hybridization (FISH)-positive and FISH-negative cases.a (C) Stage-adjusted PFS/RFS survival curves for FISH+/IHC3+ (positive) and FISH-negative/IHC0/1+ (negative) casesa aTable 2 Select model data
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in on-small-cell lung cancer. Nature. 2007;448:561–566. - PubMed
    1. Koh Y, Kim DW, Kim TM, et al. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. J Thorac Oncol. 2011;6:905–912. - PubMed
    1. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190–1203. - PubMed
    1. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009;15:3143–3149. - PubMed
    1. Wong DW, Leung EL, Wong SK, et al. A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer. 2011;117:2709–2718. - PubMed

Publication types

MeSH terms

Substances